Significantly Decreased LMK‑CT Score vs Placebo at Week 24 (Key Secondary Endpoint) With Sustained Improvement Through Week 52 (Other Secondary Endpoint) in SINUS‑521,2,a
aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.
SEE THE SCANS FROM A REAL DUPIXENT PATIENT
to see results




CT scan of patient from clinical trial. Individual results may vary.
aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.
DUPIXENT
demonstrated statistically significant reductions in opacification across all individual sinuses AT
WEEK 241,2
Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.
Explore the Safety Data and Study Designs
Administration